NDC 76413-132 Hydrocortisone Acetate

  1. Labeler Index
  2. Central Texas Community Health Centers
  3. NDC: 76413-132 Hydrocortisone Acetate

NDC Product Code 76413-132

NDC CODE: 76413-132

Proprietary Name: Hydrocortisone Acetate What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name: What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

NDC Code Structure

  • 76413 - Central Texas Community Health Centers

NDC 76413-132-12

Package Description: 12 PACKET in 1 BOX > 1 SUPPOSITORY in 1 PACKET

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

NDC Product Information

Hydrocortisone Acetate with NDC 76413-132 is a product labeled by Central Texas Community Health Centers. The generic name of Hydrocortisone Acetate is . The product's dosage form is and is administered via form.

Labeler Name: Central Texas Community Health Centers

Dosage Form: -

Product Type: What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Central Texas Community Health Centers
Labeler Code: 76413
Start Marketing Date: 07-01-1990 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date: 12-31-2019 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.
Exclude Flag: I What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Hydrocortisone Acetate Product Label Images

Hydrocortisone Acetate Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Description

Each suppository for rectal administration contains 25 mg hydrocortisone acetate USP in a hydrogenated cocoglyceride base. Hydrocortisone acetate is a corticosteroid.Chemically, hydrocortisone acetate is pregn-4-ene-3, 20 dione, 21- (acetyloxy)-11, 17-dihydroxy-, (11β)- with the following structural formula:

Clinical Pharmacology

In normal subjects, about 26 percent of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces.Topical steroids are primarily effective because of their anti-inflammatory, antipruritic and vasoconstrictive action.

Indications And Usage

For use in inflamed hemorrhoids, post irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.

Contraindications

Hydrocortisone acetate suppositories are contraindicated in those patients with a history of hypersensitivity to any of the components.

Precautions

Do not use unless adequate proctologic examination is made.If irritation develops, the product should be discontinued and appropriate therapy instituted.In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

Pregnancy Category C

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well-controlled studies in pregnant women.It is not known whether this drug is excreted in human milk.Until adequate studies in pregnant or lactating women have been conducted, this drug should be used during pregnancy or by nursing mothers only when clearly needed and when the potential benefits outweigh the potential risks.

Adverse Reactions

  • The following local adverse reactions have been reported with corticosteroid suppositories:1.Burning2.Itching3.Irritation4.Dryness5.Folliculitis6.Hypopigmentation7.Allergic Contact Dermatitis8.Secondary Infection

Drug Abuse And Dependence

Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

Overdosage

If signs and symptoms of systemic overdosage occur, discontinue use.

Usual Dosage:

One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.

How Supplied

Hydrocortisone acetate suppositories are easy to open, color coded and available in cartons of:12'sNDC 76413-132-12

Storage And Handling

Store at controlled room temperature 15° to 30°C (59° to 86°F). Protect from freezing.

Other

Manufactured ByPerrigo®Minneapolis, MN 55427(01-12)

* Please review the disclaimer below.